Navigation Links
Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results
Date:11/4/2009

al revenues of $2.1 million, compared with a net loss of $60.0 million, or $1.12 per basic and diluted share, on total revenues of $2.1 million for the same period in 2008. The net loss for the nine months ended September 30, 2009 includes a non-cash charge of $24.1 million due to a valuation adjustment relating to warrants that we issued in connection with our April 2009 registered direct offering. On a non-GAAP basis, excluding the $24.1 million non-cash charge, our net loss for the first nine months of 2009 was $66.5 million, or $1.15 per basic and diluted share, compared with a GAAP net loss of $60.0 million for the nine months ended September 30, 2008, or $1.12 per basic and diluted share.

Financial Results of Operations for the Three Months Ended September 30, 2009

Total revenues for the third quarter of 2009 were $0.3 million compared with $0.5 million for the third quarter of 2008, a decrease of $0.2 million mainly due to lower gross sales of Oxandrin® as a result of decreased overall demand for the product from increased generic competition. Additionally, we adjusted our Oxandrin product return reserve in both the current and prior year quarters to reflect higher actual return experience. We expect that sales of Oxandrin will continue to decline slightly or remain flat in future periods. The decrease in Oxandrin sales was partially offset by a $0.1 million increase in sales of our authorized generic oxandrolone, due to increased market share being achieved by Watson Pharmaceuticals, Inc. (Watson), our authorized generic distributor.

Research and development expenses for the third quarter of 2009 were $17.7 million, compared with $10.9 million for the third quarter of 2008, an increase of $6.8 million, or 62%. The increase is primarily due to $4.5 million in contingency charges recorded in the third quarter of 2009 relating to amending the fee schedule and total obligation under our services agreement with
'/>"/>

SOURCE Savient Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine technology :

1. Savient Announces FDAs Advisory Panel to Review Pegloticase for Treatment-Failure Gout Patients
2. Savient Provides Update on Pegloticase BLA
3. Savient Pharmaceuticals Announces Proposed Public Offering of Common Stock
4. Savient Pharmaceuticals Prices Underwritten Offering of Common Stock
5. Savient Pharmaceuticals Announces Closing of Public Offering and Exercise of Over-Allotment Option
6. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
7. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
8. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
9. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
10. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
11. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... HILL, N.C. , March 27, 2015 ... is essential to meeting challenges in clinical development, market ... face tighter regulations, the Medical Affairs function is expected ... by mature markets. According to research ... study participants have a group dedicated to Medical Affairs. ...
(Date:3/27/2015)... March 27, 2015 /PRNewswire/ - Medicure Inc. (the "Company") ... has approved the grant of an aggregate of 236,070 ... and consultants of the Company pursuant to the Company,s ... to expire on the tenth anniversary of the date ... third anniversary of the date of grant and 50,000 ...
(Date:3/27/2015)... 27, 2015  Victoria Vein & Surgery Clinic is the ... Duality laser in Victoria, Texas . The ... as advanced laser treatments for a variety of medical and ... to provide more services for their patients. Since adding laser ... Victoria residents get rid of their unwanted ...
Breaking Medicine Technology:Medical Affairs Capabilities Expanding in Emerging Marketplaces 2Victoria Vein And Surgery Clinic Uses Advanced Astanza Duality Tattoo Removal Technology 2
... RENO, Nev., April 12, 2011 Visual Healthcare Corp. (the ... on a Chinese based adaptation of the information technology grid ... This project has been launched in response to ... Research Organization experts responding to Chinese government resolve to create ...
... Md., April 12, 2011 Neuralstem, Inc. (NYSE Amex: ... Ph.D., Principal Investigator of the Phase I safety trial ... amyotrophic lateral sclerosis (ALS or Lou Gehrig,s disease), and ... first nine patients. Dr. Feldman reported yesterday at the ...
Cached Medicine Technology:Visual Healthcare to Support Chinese Clinical Trials 2Visual Healthcare to Support Chinese Clinical Trials 3Dr. Eva Feldman, Principal Investigator, Presents Interim Safety Results for Neuralstem ALS Trial 2Dr. Eva Feldman, Principal Investigator, Presents Interim Safety Results for Neuralstem ALS Trial 3Dr. Eva Feldman, Principal Investigator, Presents Interim Safety Results for Neuralstem ALS Trial 4
(Date:3/28/2015)... Early surgery may not be the ... joint injuries, according to new research from Tripler Army ... Orthopaedic Society for Sports Medicine’s ( AOSSM ) Specialty ... surgery was not performed. , The final study group ... and 17 receiving non-surgical therapy. Of the non-surgery group, ...
(Date:3/28/2015)... La Mirada, CA (PRWEB) March 28, 2015 ... with ear, nose and throat disorders, are ... Tinnitus is a common issue which is characterized by ... ears. Affecting 1 in 5 people, tinnitus is a ... or disorder and while it is non-fatal, tinnitus can ...
(Date:3/28/2015)... 2015 Servpro of Paso Robles ... released a report about the link between mold and ... and according to recent medical research, may even cause ... the Environmental Protection Agency, people with sensitivity to mold ... mold may trigger asthma attacks for asthma sufferers. The ...
(Date:3/27/2015)... Florida Hospital is excited to continue its partnership with the ... for the 2015 and 2016 season. As the Storm’s exclusive ... athletic trainer for the team throughout each season. Tonight, the ... Cleveland Gladiators at Amalie Arena; the game starts at 7:30pm. ... as it gives us the opportunity, to provide health and ...
(Date:3/27/2015)... (PRWEB) March 27, 2015 Healthpointe is ... G. Katz, M.D., is now treating knee and hip ... Anaheim , Long Beach, and La Mirada. Dr. ... acute knee and hip joint disorders as well as ... is passionate in returning his patients back to their ...
Breaking Medicine News(10 mins):Health News:For Type V AC Joint Injuries, Early Surgery May Not Be the Best Approach 2Health News:Healthpointe now Offering Tinnitus Treatments in Clinics throughout Southern California 2Health News:Water Damage Restoration Specialists Servpro of Paso Robles Release Report on Mold and Asthma 2Health News:Water Damage Restoration Specialists Servpro of Paso Robles Release Report on Mold and Asthma 3Health News:Florida Hospital Is Kicking off the 2015 Season as the Exclusive Health Care Provider for the Tampa Bay Storm 2Health News:Florida Hospital Is Kicking off the 2015 Season as the Exclusive Health Care Provider for the Tampa Bay Storm 3Health News:Fellowship-Trained and Board-Certified Orthopedic Surgeon is Now Treating Knee and Hip Joint Disorders in Anaheim, California 2Health News:Fellowship-Trained and Board-Certified Orthopedic Surgeon is Now Treating Knee and Hip Joint Disorders in Anaheim, California 3
... , ... ... ... ...
... Farmers, markets are not created equal. Some sell only ... of vendors. And each market,s unique personality attracts some people ... based on what they offer, farmers, markets self-select people who ... stores isn,t one of them. "Not one of the ...
... ... ... ... ...
... ... ... ... ...
... ... ... , , ... ...
... ... ... , ... , , , ...
Cached Medicine News:Health News:Health Groups Ask Supreme Court to Authorize Financial Penalties on Tobacco Companies for Decades of Wrongdoing 2Health News:Health Groups Ask Supreme Court to Authorize Financial Penalties on Tobacco Companies for Decades of Wrongdoing 3Health News:Farmers' markets offer different strokes for different folks 2Health News:Farmers' markets offer different strokes for different folks 3Health News:Census Bureau News -- 2007 Economic Census: Health Care and Social Assistance Geographic Area Series (NAICS 62) 2Health News:Abbott Announces 10 Percent Increase in Quarterly Dividend 2Health News:Abbott Announces 10 Percent Increase in Quarterly Dividend 3Health News:Massachusetts Hospital Agrees to Pay U.S. $2.79 Million to Resolve False Claims Act Allegations 2Health News:With Record Registration of 13,000 Runners to Date, the 2010 Dick's Sporting Goods Pittsburgh Marathon Announces a Cap of 16,000 2Health News:With Record Registration of 13,000 Runners to Date, the 2010 Dick's Sporting Goods Pittsburgh Marathon Announces a Cap of 16,000 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: